Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICP-332 MAD Phase I Study in Healthy Subjects
NCT06530966Phase 1Completed
- Sponsor
- InnoCare Pharma
- Start
- Jul 2024
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial comparing ICP-332 with Placebo (2 arms). Primary endpoints: Number of participants with Adverse Events at 28 days, Number of Participants With Clinically Significant Change in Vital Signs at 28 days and 3 more. Started Jul 2024; status: completed.
02
Drugs
soficitinib
Beyond the preview
Go deeper on NCT06530966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530966.